企業
企業
矢印は関係の方向を示します。分野で絞り込めます。
Mediar is also progressing novel fibro-inflammatory targets as part of a recently announced collaboration with Ono Pharmaceutical.出典を見る
Mediar is conducting the Phase 2 WISPer study under a global licensing agreement with Eli Lilly and Company.出典を見る
2 件中 1 から 2 件を表示
出典とともに結論を確認し、項目を開いて証拠を読めます。
Mediar is also progressing novel fibro-inflammatory targets as part of a recently announced collaboration with Ono Pharmaceutical.
PR Newswire news releases · 2026-10-07 19:08
Mediar is also progressing novel fibro-inflammatory targets as part of a recently announced collaboration with Ono Pharmaceutical.出典を見る
Mediar is conducting the Phase 2 WISPer study under a global licensing agreement with Eli Lilly and Company.
PR Newswire news releases · 2026-10-07 19:08
Mediar is conducting the Phase 2 WISPer study under a global licensing agreement with Eli Lilly and Company.出典を見る
2 件中 1 から 2 件を表示
バリュエーションは Pro と Research で利用できます。
Pro で解放利用できません: 企業シグナル · 財務 · 開示資料 · ガイダンス
